

Serial No.: 10/051,770 (ADDENDUM)

- A1 -

ADDENDUM TO PRELIMINARY AMENDMENT DATED AUGUST 28, 2002

MARKED-UP VERSION OF AMENDED CLAIMS

1. (Amended) A method for treating an addiction disorder in a patient, said method comprising:

administering to the patient a first $\alpha_3\beta_4$ nicotinic receptor antagonist; and

administering to the patient a second $\alpha_3\beta_4$ nicotinic receptor antagonist; wherein the second $\alpha_3\beta_4$ nicotinic receptor antagonist is different than the first $\alpha_3\beta_4$ nicotinic receptor antagonist and wherein the first $\alpha_3\beta_4$ nicotinic receptor antagonist and the second $\alpha_3\beta_4$ nicotinic receptor antagonist are administered simultaneously or non-simultaneously;

provided that, when the first $\alpha_3\beta_4$ nicotinic receptor antagonist is dextromethorphan, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not dextrophan; and

further provided that, when the first $\alpha_3\beta_4$ nicotinic receptor antagonist is dextrophan, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not dextromethorphan; and

further provided that, when the addiction disorder is a nicotine addiction disorder and when first $\alpha_3\beta_4$ nicotinic receptor antagonist is dextromethorphan, dextrophan, or mecamylamine, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not bupropion; and

I:\010\00141\25

Serial No.: 10/051,770 (ADDENDUM)

- A2 -

further provided that, when the addiction disorder is a nicotine addiction disorder and when the first $\alpha_3\beta_4$ nicotinic receptor antagonist is bupropion, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not dextromethorphan, dextrorphan, or mecamylamine.

21. (Amended) A composition comprising:

a first $\alpha_3\beta_4$ nicotinic receptor antagonist; and

a second $\alpha_3\beta_4$ nicotinic receptor antagonist; wherein the second $\alpha_3\beta_4$ nicotinic receptor antagonist is different than the first $\alpha_3\beta_4$ nicotinic receptor antagonist;

provided that, when the first $\alpha_3\beta_4$ nicotinic receptor antagonist is dextromethorphan, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not dextrorphan; and

further provided that, when the first $\alpha_3\beta_4$ nicotinic receptor antagonist is dextrorphan, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not dextromethorphan; and

further provided that, when first $\alpha_3\beta_4$ nicotinic receptor antagonist is dextromethorphan, dextrorphan, or mecamylamine, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not bupropion; and

further provided that, when the first $\alpha_3\beta_4$ nicotinic receptor antagonist is bupropion, the second $\alpha_3\beta_4$ nicotinic receptor antagonist is not dextromethorphan, dextrorphan, or mecamylamine.

I:\010\00141\25

Serial No.: 10/051,770 (ADDENDUM)

- A3 -

34. (Amended) A composition comprising:

a first compound selected from the group consisting of mecamlamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and [phamaceutically] pharmaceutically acceptable salts and solvates thereof; and

a second [$\alpha_3\beta_4$] compound selected from the group consisting of mecamlamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and [phamaceutically] pharmaceutically acceptable salts and solvates thereof; wherein the second compound is different than the first compound;

provided that, when the first compound is dextromethorphan, the second compound is not dextrorphan; and

further provided that, when the first compound is dextrorphan, the second compound is not dextromethorphan; and

further provided that, when first compound is dextromethorphan, dextrorphan, or mecamlamine, the second compound is not bupropion; and

further provided that, when the first compound is bupropion, the second compound is not dextromethorphan, dextrorphan, or mecamlamine.

35. (Amended) A method of evaluating a compound for its effectiveness in treating addiction disorders other than nicotine addiction disorders, said method comprising:

assessing the compound's ability to bind to $\alpha_3\beta_4$ nicotinic receptors.

I:\010\00141\25

Serial No.: 10/051,770 (ADDENDUM)

- A4 -

37. (Amended) A method for treating an addiction disorder in a patient, said method comprising:

administering to the patient an $\alpha_3\beta_4$ nicotinic receptor antagonist under conditions effective to treat the patient's addiction disorder;

provided that the $\alpha_3\beta_4$ nicotinic receptor antagonist is neither dextromethorphan nor dextrorphan; and

further provided that, when the addiction disorder is a nicotine addiction disorder, the $\alpha_3\beta_4$ nicotinic receptor antagonist is neither bupropion nor mecamylamine.

38. (Amended) A method according to claim 37, wherein the $\alpha_3\beta_4$ nicotinic receptor antagonist is not mecamylamine; is not 18-methoxycoronaridine; is not bupropion; [is not dextromethorphan; is not dextrorphan,] is not ibogaine; and is not a [pharmaceutically] pharmaceutically acceptable salt or solvate of mecamylamine, 18-methoxycoronaridine, bupropion, [dextromethorphan, dextrorphan,] or ibogaine.

I:\010\00141\25